Antidepressant Drugs Market,Share Size and Forecast 2019-2026

SKU: DHC255 | Last Updated On: Jul 31 2019 | No. of Pages: 217 | Available Formats

 

Antidepressant Drugs Market

The Global Antidepressant Drugs market was valued at USD XX million in 2018 and expected to grow at a CAGR of XX% to reach a market value of USD XX million by 2026.

Antidepressants are medications that can help relieve depression symptoms. The objective is to correct the chemical imbalances of neurotransmitters in the brain that are believed to be responsible for changes in behavior and mood. They can also be used to treat several other conditions, including generalized anxiety disorder, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and are sometimes used when treating people with chronic pains. Although antidepressants can treat the symptoms of depression, they don't address the causes, hence are typically used in combination with other therapies.

Global Antidepressant Drugs Market Dynamics

 

The global market for the Antidepressant Drugs The market is primarily driven by the increase in the prevalence of depression, raising awareness regarding depression, and required clinical needs. According to WHO, depression affects 300 million people worldwide and is a common illness. Depression can become a severe health condition when long-lasting with moderate or severe intensity and can even lead to suicide. According to the WHO, there were an estimated 793,000 suicide deaths worldwide in 2016, and approximately 800,000 people die due to suicide every year. Moreover, the rising number of people suffering from stress, the emergence of novel drugs with lesser side-effects and growing elderly population, who are prone to suffer from subsyndromal depression, are expected to drive the market further. An estimated 70.9 million prescriptions for antidepressants were given in England in 2018, which has almost doubled in the past decade when compared with 36 million given out in 2008.

However, the preference of non-pharmacological therapies over pharmacological therapies, its reduced efficacy and patent expiry of antidepressants leading to a weak pipeline may hinder market progress. 

Global Antidepressant Drugs Market – Segment Analysis

By Drug Class, the global Antidepressant Drugs market is segmented into Monoamine oxidase inhibitors, Norepinephrine-Dopamine Reuptake Inhibitor, Serotonin-norepinephrine reuptake inhibitors, Selective serotonin reuptake inhibitors, Tricyclic antidepressants, and others. Selective serotonin reuptake inhibitors (SSRIs) hold the most substantial market share and are the most commonly prescribed antidepressants owing to efficacy and safety. Moreover, they have fewer side effects than other antidepressants.

By depression disorder, the global antidepressant drugs market is segmented into major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, panic disorder, and others. The major depressive disorder is the most prevalent as it can be caused by a combination of distress from psychological, biological, and social sources. Some significant risk factors include chronic health problems, substance abuse, family history, and drastic life changes. According to the CDC, an estimated 17.3 million adults in the US had at least one major depressive episode, which represented 7.1% of all US adults. A CDC study shows that postpartum depression estimates can be as high as 1 in 5 women in the US.

Global Antidepressant Drugs Market– Geographical Analysis

 

North America accounts for the largest share in the global antidepressant drugs market. This can be mainly attributed to factors the increasing prevalence of depression and government incentives to promote awareness regarding depression. According to the CDC, more than 8% of adults older than 20 reported having depression during a given two-week period in the US. According to the Anxiety Disorders Association of America, in the US, anxiety disorders are the most common mental illness affecting 40 million adults (18.1%) age 18 and older annually. Generalized anxiety disorder affects 6.8 million (3.1%) adults, panic disorder affects 6 million (2.7%) adults, and post-traumatic stress disorder affects 7.7 million (3.5%) adults, major depressive disorder affects more than 16.1 million (6.7%) the US adults, and persistent depressive disorder, also known as dysthymia, affects approximately 1.5% of the US population. Moreover, the advanced regional healthcare infrastructure, easy availability of medication, the presence of established market players, and high investment in R&D activities by them are likely to boost the North America antidepressant drugs market growth.

Global Antidepressant Drugs Market– Competitive Analysis

Companies are increasing their user base and improving their antidepressant drugs market presence by FDA approvals and investing in R&D. Moreover, several key companies have adopted merger and acquisitions policies, geographic expansion, and collaborations to gain competitors edge in the market and also to expand its sales in the global antidepressant drugs market.

Major Players in the global anti-depressant drugs market include Allergan plc, Pfizer Inc., Novartis AG, AstraZeneca PLC, and Johnson & Johnson.

In May 2019, Allergan plc and Gedeon Richter Plc. announced FDA approval of supplemental New Drug Application (sNDA) for VRAYLAR (cariprazine) for expanded use to treat depressive episodes associated with bipolar depression in adults. VRAYLAR is also approved in the U.S. to treat manic or mixed episodes associated with bipolar I disorder in adults.

In March 2019, the FDA approved a Johnson & Johnson nasal spray antidepressant for people resistant to other treatments. The drug, a nasal spray called Spravato (esketamine) acts within hours, rather than weeks or months as is typical for current antidepressants.

In March 2019, Sage Therapeutics received FDA approval for ZULRESSO (brexanolone) injection for the treatment of postpartum depression (PPD). ZULRESSO is the only specifically approved drug for the treatment of PPD, the most common medical complication of childbirth.

In July 2018, FDA granted fast track designationfor Allergan’s investigational new treatment for the major depressive disorder - AGN-241751. AGN-241751 is a novel, oral, rapid-acting anti-depressant that recently entered Phase 2 development. 

In July 2015, FDA approved Otsuka’s Rexulti (brexpiprazole) for the treatment of depression and schizophrenia.

Key Takeaways:

·       The global market for the Antidepressant Drugs Market is primarily driven by the increase in the prevalence of depression, raising awareness regarding depression, and required clinical needs.

·       Selective serotonin reuptake inhibitors (SSRIs) hold the most substantial market share and are the most commonly prescribed antidepressants owing to efficacy and safety.

·       North America accounts for the dominant share in the global antidepressant drugs market. This can be mainly attributed to factors the increasing prevalence of depression and government incentives to promote awareness regarding depression.

·       Companies are increasing their user base and improving their Antidepressant Drugs market presence by FDA approvals and investing in R&D. For instance, in July 2015, FDA Approved Rexulti (brexpiprazole) from Otsuka for the treatment of depression and schizophrenia.

Why Purchase the Report?

·       Visualize the composition of the global Antidepressant Drugs Market across each indication, in terms of Type and Application options, highlighting the key commercial assets and players.

·       Identify commercial opportunities in global Antidepressant Drugs Market by analyzing trends and co-development deals.

·       Excel data sheet with thousands of data points of the global Antidepressant Drugs Market - level 4/5 segmentation.

·       PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

·       Type mapping in excel for the key Services of all major market players

Target Audience:

·       Equipment Suppliers/ Buyers

·       Type Providers/ Buyers

·       Industry Investors/Investment Bankers

·       Education & Research Institutes

·       Research Professionals

·       Emerging Companies

Manufacturers 

 

Global Antidepressant Drugs Market

1. Global Antidepressant Drugs Market -Scope and Methodology

1.1. Research Methodology

1.2. Scope of the market

2. Global Antidepressant Drugs Market -Key Trends and Developments

2.1. Key Trends and Developments

3. Global Antidepressant Drugs Market – Executive Summary

3.1. Market Snippet By Drug Class

3.2. Market Snippet By Depression Disorder

3.3. Market Snippet By Region

3.4. DataM CLO Scenario

4. Global Antidepressant Drugs Market – Market Dynamics

4.1. Market impacting factors

4.2. Drivers

4.2.1. Increase in prevalence of depression

4.2.2. Rise in geriatric population

4.2.3. Driver 3

4.3. Restraints

4.3.1. Preference of non-pharmacological therapies over pharmacological therapies

4.3.2. Restraint 2

4.4. Opportunity

5. Impact analysis

6. Global Antidepressant Drugs Market – Industry Analysis

6.1. Porter's five forces analysis

6.2. Epidemiology Analysis

6.3. Pipeline analysis

7. Global Antidepressant Drugs Market – By Drug Class

7.1. Introduction

7.2. Market size analysis, and y-o-y growth analysis (%), By Drug Class segment

7.3. Market attractiveness index, By Drug Class segment

7.4. Monoamine oxidase inhibitors (MAOIs)

7.4.1. Introduction

7.4.2. Market size analysis, y-o-y growth analysis (%)

7.5. Norepinephrine-Dopamine Reuptake Inhibitor  (NDRI)

7.6. Serotonin-norepinephrine reuptake inhibitors (SNRIs)

7.7. Selective serotonin reuptake inhibitors (SSRIs)

7.8. Tricyclic antidepressants (TCAs)

7.9. Others

8. Global Antidepressant Drugs Market – By Depression Disorder

8.1. Introduction

8.2. Market size analysis, and y-o-y growth analysis (%), By Depression Disorder segment

8.3. Market attractiveness index, By Depression Disorder segment

8.4. Major depressive disorder

8.4.1. Introduction

8.4.2. Market size analysis, and y-o-y growth analysis (%)

8.5. Obsessive-compulsive disorder

8.6. Generalized anxiety disorder

8.7. Panic disorder

8.8. Others

9. Global Antidepressant Drugs Market – By Region

9.1. Introduction

9.2. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region

9.3. Market Attractiveness Index, By Region

9.4. North America

9.4.1. Introduction

9.4.2. Key region-specific dynamics

9.4.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug Class

9.4.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Depression Disorder

9.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries

9.4.5.1.          U.S.

9.4.5.2.         Canada

9.4.5.3.         Mexico

9.5. Europe

9.5.1. Introduction

9.5.2. Key Region-Specific Dynamics

9.5.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug Class

9.5.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Depression Disorder

9.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries

9.5.5.1.          Germany

9.5.5.2.         U.K.

9.5.5.3.         France

9.5.5.4.         Italy

9.5.5.5.         Spain

9.5.5.6.         Rest of Europe

9.6. South America

9.6.1. Introduction

9.6.2. Key Region-Specific Dynamics

9.6.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug Class

9.6.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Depression Disorder

9.6.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries

9.6.5.1.          Brazil

9.6.5.2.         Argentina

9.6.5.3.         Rest of South America

9.7. Asia Pacific

9.7.1. Introduction

9.7.2. Key Region-Specific Dynamics

9.7.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug Class

9.7.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Depression Disorder

9.7.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries

9.7.5.1.          China

9.7.5.2.         India

9.7.5.3.         Japan

9.7.5.4.         Australia

9.7.5.5.         Rest of Asia Pacific

9.8. The Middle East And Africa

9.8.1. Introduction

9.8.2. Key Region-Specific Dynamics

9.8.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug Class

9.8.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Depression Disorder

10. Global Antidepressant Drugs Market – Competitive Landscape

10.1. Competitive scenario

10.2. Market positioning/share analysis

10.3. Comparative type portfolio analysis

10.4. Mergers and acquisitions analysis

11. Company Profiles

11.1. Allergan plc.

11.1.1. Company Overview

11.1.2. Type Portfolio And Description

11.1.3. Key Highlights

11.1.4. Financial Overview

11.2. AstraZeneca PLC

11.3. GlaxoSmithKline plc

11.4. Pfizer Inc.

11.5. Eli Lilly & Company Ltd.

11.6. Johnson & Johnson

11.7. Takeda Pharmaceutical Co. Ltd.

11.8. H. Lundbeck AS

11.9. Otsuka Holdings Co., Ltd.

11.10. Novartis AG

12. Global Antidepressant Drugs Market – Premium Insights

13. Global Antidepressant Drugs Market – DataM

13.1. Appendix

13.2. About us and services

13.3. Contact us

 

LIST OF TABLES

Table 1 Global Antidepressant Drugs Market Value, By Drug Class, 2018,2022 & 2026 ($ Million)

Table 2 Global Antidepressant Drugs Market Value, By Depression Disorder, 2018,2022 & 2026 ($ Million)

Table 3 Global Antidepressant Drugs Market Value, By Region, 2018,2022 & 2026 ($ Million)

Table 4 Global Antidepressant Drugs Market Value, By Drug Class, 2018,2022 & 2026 ($ Million)

Table 5 Global Antidepressant Drugs Market Value, By Drug Class, 2017-2026 ($ Million)

Table 6 Global Antidepressant Drugs Market Value, By Depression Disorder, 2018,2022 & 2026 ($ Million)

Table 7 Global Antidepressant Drugs Market Value, By Depression Disorder, 2017-2026 ($ Million)

Table 8 Global Antidepressant Drugs Market Value, By Region, 2018,2022 & 2026 ($ Million)

Table 9 Global Antidepressant Drugs Market Value, By Region, 2017-2026 ($ Million)

Table 10 North America Antidepressant Drugs Market Value, By Drug Class, 2017-2026 ($ Million)

Table 11 North America Antidepressant Drugs Market Value, By Depression Disorder, 2017-2026 ($ Million)

Table 12 North America Antidepressant Drugs Market Value, By Country, 2017-2026 ($ Million)

Table 13 South America Antidepressant Drugs Market Value, By Drug Class, 2017-2026 ($ Million)

Table 14 South America Antidepressant Drugs Market Value, By Depression Disorder, 2017-2026 ($ Million)

Table 15 South America Antidepressant Drugs Market Value, By Country, 2017-2026 ($ Million)

Table 16 Europe Antidepressant Drugs Market Value, By Drug Class, 2017-2026 ($ Million)

Table 17 Europe Antidepressant Drugs Market Value, By Depression Disorder, 2017-2026 ($ Million)

Table 18 Europe Antidepressant Drugs Market Value, By Country, 2017-2026 ($ Million)

Table 19 Asia-Pacific Antidepressant Drugs Market Value, By Drug Class, 2017-2026 ($ Million)

Table 20 Asia-Pacific Antidepressant Drugs Market Value, By Depression Disorder, 2017-2026 ($ Million)

Table 21 Asia-Pacific Antidepressant Drugs Market Value, By Country, 2017-2026 ($ Million)

Table 22 The Middle East & Africa Antidepressant Drugs Market Value, By Drug Class, 2017-2026 ($ Million)

Table 23 The Middle East & Africa Antidepressant Drugs Market Value, By Depression Disorder, 2017-2026 ($ Million)

Table 24 Allergan Inc: Overview

Table 25 Allergan Inc: Product Portfolio

Table 26 Allergan Inc: Key Developments

Table 27 AstraZeneca PLC: Overview

Table 28 AstraZeneca PLC: Product Portfolio

Table 29 AstraZeneca PLC: Key Developments

Table 30 GlaxoSmithKline plc: Overview

Table 31 GlaxoSmithKline plc: Product Portfolio

Table 32 GlaxoSmithKline plc: Key Developments

Table 33 Pfizer Inc.: Overview

Table 34 Pfizer Inc.: Product Portfolio

Table 35 Pfizer Inc.: Key Developments

Table 36 Eli Lilly & Company Ltd.: Overview

Table 37 Eli Lilly & Company Ltd.: Product Portfolio

Table 38 Eli Lilly & Company Ltd.: Key Developments

Table 39 Johnson & Johnson: Overview

Table 40 Johnson & Johnson: Product Portfolio

Table 41 Johnson & Johnson: Key Developments

Table 42 Takeda Pharmaceutical Co. Ltd.: Overview

Table 43 Takeda Pharmaceutical Co. Ltd.: Product Portfolio

Table 44 Takeda Pharmaceutical Co. Ltd.: Key Developments

Table 45 H. Lundbeck AS: Overview

Table 46 H. Lundbeck AS: Product Portfolio

Table 47 H. Lundbeck AS: Key Developments

Table 48 Otsuka Holdings Co., Ltd.: Overview

Table 49 Otsuka Holdings Co., Ltd.: Product Portfolio

Table 50 Otsuka Holdings Co., Ltd.: Key Developments

Table 51 Novartis AG: Overview

Table 52 Novartis AG: Product Portfolio

Table 53 Novartis AG: Key Developments

LIST OF FIGURES

Figure 1 Global Antidepressant Drugs Market Share, By Drug Class, 2018 & 2026 (%)

Figure 2 Global Antidepressant Drugs Market Share, By Depression Disorder, 2018 & 2026 (%)

Figure 3 Global Antidepressant Drugs Market Share, By Region, 2018 & 2026 (%)

Figure 4 Global Antidepressant Drugs Market Value, 2017-2026 ($ Million)

Figure 5 Global Antidepressant Drugs Market Y-o-Y Growth, By Drug Class, 2018-2026 (%)

Figure 6 Monoamine oxidase inhibitors: Global Antidepressant Drugs Market Value, 2017-2026 ($ Million)

Figure 7 Norepinephrine-Dopamine Reuptake Inhibitor: Global Antidepressant Drugs Market Value, 2017-2026 ($ Million)

Figure 8 Serotonin-norepinephrine reuptake inhibitors: Global Antidepressant Drugs Market Value, 2017-2026 ($ Million)

Figure 9 Selective serotonin reuptake inhibitors: Global Antidepressant Drugs Market Value, 2017-2026 ($ Million)

Figure 10 Tricyclic antidepressants: Global Antidepressant Drugs Market Value, 2017-2026 ($ Million)

Figure 11 Others: Global Antidepressant Drugs Market Value, 2017-2026 ($ Million)

Figure 12 Global Antidepressant Drugs Market Y-o-Y Growth, By Depression Disorder, 2018-2026 (%)

Figure 13 Major depressive disorder: Global Antidepressant Drugs Market Value, 2017-2026 ($ Million)

Figure 14 Obsessive-compulsive disorder: Global Antidepressant Drugs Market Value, 2017-2026 ($ Million)

Figure 15 Global Antidepressant Drugs Market Y-o-Y Growth, By Region, 2018-2026 (%)

Figure 16 North America Antidepressant Drugs Market Value, 2017-2026 ($ Million)

Figure 17 North America Antidepressant Drugs Market Share, By Drug Class, 2018 & 2026 (%)

Figure 18 North America Antidepressant Drugs Market Share, By Depression Disorder, 2018 & 2026 (%)

Figure 19 North America Antidepressant Drugs Market Share, By Country, 2018 & 2026 (%)

Figure 20 South America Antidepressant Drugs Market Value, 2017-2026 ($ Million)

Figure 21 South America Antidepressant Drugs Market Share, By Drug Class, 2018 & 2026 (%)

Figure 22 South America Antidepressant Drugs Market Share, By Depression Disorder, 2018 & 2026 (%)

Figure 23 South America Antidepressant Drugs Market Share, By Country, 2018 & 2026 (%)

Figure 24 Europe Antidepressant Drugs Market Value, 2017-2026 ($ Million)

Figure 25 Europe Antidepressant Drugs Market Share, By Drug Class, 2018 & 2026 (%)

Figure 26 Europe Antidepressant Drugs Market Share, By Depression Disorder, 2018 & 2026 (%)

Figure 27 Europe Antidepressant Drugs Market Share, By Country, 2018 & 2026 (%)

Figure 28 Asia-Pacific Antidepressant Drugs Market Value, 2017-2026 ($ Million)

Figure 29 Asia-Pacific Antidepressant Drugs Market Share, By Drug Class, 2018 & 2026 (%)

Figure 30 Asia-Pacific Antidepressant Drugs Market Share, By Depression Disorder, 2018 & 2026 (%)

Figure 31 Asia-Pacific Antidepressant Drugs Market Share, By Country, 2018 & 2026 (%)

Figure 32 The Middle East & Africa Antidepressant Drugs Market Value, 2017-2026 ($ Million)

Figure 33 The Middle East & Africa Antidepressant Drugs Market Share, By Drug Class, 2018 & 2026 (%)

Figure 34 The Middle East & Africa Antidepressant Drugs Market Share, By Depression Disorder, 2018 & 2026 (%)

Figure 35 Allergan Inc: Financials

Figure 36 AstraZeneca PLC: Financials

Figure 37 GlaxoSmithKline plc: Financials

Figure 38 Pfizer Inc.: Financials

Figure 39 Eli Lilly & Company Ltd.: Financials

Figure 40 Johnson & Johnson: Financials

Figure 41 Takeda Pharmaceutical Co. Ltd.: Financials

Figure 42 H. Lundbeck AS: Financials

Figure 43 Otsuka Holdings Co., Ltd.: Financials

Figure 44 Novartis AG: Financials

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Get your FREE SAMPLE PROPOSAL with a single click!